Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology Stock Forecast

Stock Price Forecast

The 3 analysts that cover Cardiff Oncology stock have a consensus rating of "Strong Buy" and an average price target of $10.83, which forecasts a 285.41% increase in the stock price over the next year. The lowest target is $3.50 and the highest is $19.

Price Target: $10.83 (+285.41%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.50	$10.83	$10	$19
Change	+24.56%	+285.41%	+255.87%	+576.16%

* Price targets were last updated on Aug 6, 2025.

Analyst Ratings

The average analyst rating for Cardiff Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26
Strong Buy	4	4	4	4	4	2
Buy	1	1	1	1	1	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $18 → $10	Strong Buy	Maintains	$18 → $10	+255.87%	Aug 6, 2025
Kevin DeGeeter Ladenburg Thalmann	Ladenburg Thalmann	Strong Buy Initiates $19	Strong Buy	Initiates	$19	+576.16%	Jul 8, 2025
Maury Raycroft Jefferies	Jefferies	Hold Initiates $3.5	Hold	Initiates	$3.5	+24.56%	Jun 24, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $17 → $18	Strong Buy	Maintains	$17 → $18	+540.57%	May 9, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $13 → $17	Strong Buy	Maintains	$13 → $17	+504.98%	Feb 28, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

470.33K

Decreased by -31.14%

from 683.00K

Revenue Next Year

373.43K

Decreased by -20.60%

from 470.33K

EPS This Year

-0.78

from -0.95

EPS Next Year

-0.77

from -0.78

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	366.00K	359.00K	386.00K	488.00K	683.00K	470.33K	373.43K
Revenue Growth	49.61%	-1.91%	7.52%	26.42%	39.96%	-31.14%	-20.60%
EPS	-1.08	-0.73	-0.89	-0.93	-0.95	-0.78	-0.77
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	11	11

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	525,000	729,750
Avg	470,332	373,432
Low	343,000	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	-23.1%	55.2%
Avg	-31.1%	-20.6%
Low	-49.8%	-

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-0.78	-0.58
Avg	-0.78	-0.77
Low	-0.82	-0.95

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.